Who Really Leads the Continuous Glucose Monitoring Devices Market? A Share Breakdown

Continuous glucose monitoring (CGM) has moved from a niche tool for Type 1 diabetes to a mainstream part of connected diabetes care. Grand View Research values the global continuous glucose monitoring devices market at USD 13.4 billion in 2025. It projects growth to USD 15.5 billion in 2026 and USD 41.4 billion by 2033, a 15.1% CAGR. Here is who is winning, who is challenging them, and which technologies set them apart.

Market Leaders and Share

The competitive picture is concentrated. DexCom, Abbott Laboratories, and Medtronic hold the most significant positions. Their advantage comes from recurring sensor revenue, broad reimbursement coverage, large installed user bases, and ecosystems that combine sensors, apps, cloud analytics, and insulin delivery.

The share data points to where that revenue comes from:

• Sensors led the product segment with 62.8% of 2025 revenue, because they are replaced every 10-15 days.
• Bluetooth led connectivity with 57.3%.
• Type 1 diabetes led indications with 64.9%.
• Pharmacies led distribution with 59.4%.
• North America held 63.3% of regional revenue, with the U.S. as the largest country market. Asia Pacific is the fastest-growing region.

Recent moves from the leaders show their strategy:

• DexCom received FDA clearance for the Dexcom G7 15 Day system in April 2025. In March 2024 it won approval for Stelo, an over-the-counter CGM for non-insulin-using Type 2 and wellness users.
• Abbott announced FreeStyle Libre 2 Plus integration with Tandem's t:slim X2 pump in January 2024. In August 2024 it partnered with Medtronic on automated insulin delivery integration.
• Medtronic received FDA approval for the Simplera CGM in July 2024. It also earned CE Mark approval in Europe for the MiniMed 780G with Simplera Sync in January 2024.

Download Free Sample: preview the data, trends, and forecasts.

Market Competitors and Core Technology

Behind the big three is a growing field of challengers. Grand View Research lists emerging players including Senseonics, Tandem Diabetes Care, Ascensia Diabetes Care, AgaMatrix, GlucoRx, Zhejiang POCTech, and i-SENS. Roche, Insulet, Sinocare, and Bionime are also profiled or named in the competitive landscape. These companies tend to compete on faster innovation cycles, lower prices, and regional focus rather than scale. Their main constraints are smaller commercial infrastructure and the cost of winning global approvals and clinical evidence.

The technologies that define competition include:

• Implantable sensing: Senseonics' Eversense 365, approved by the FDA in September 2024, is the first implantable CGM lasting up to a year. It doubles the longevity of its predecessor and works with insulin pumps.
• Smaller, faster sensors: Dexcom G7 and Abbott's Libre 3 are more compact and discreet. Extended wear, such as 15-day sensors, reduces the hassle of changes.
• Connectivity: Bluetooth dominates today. NFC is projected to grow at a 19.54% CAGR, helped by low power use, lower cost, and smartphone compatibility, especially in emerging markets.
• Automated insulin delivery integration: Partnerships between CGM makers and pump companies are turning standalone sensors into closed-loop systems.
• AI analytics and digital ecosystems: Predictive alerts, cloud sharing, and remote monitoring turn raw readings into actionable trends. Dexcom's data integration with the Oura Ring is one example.
• OTC access: Products like Stelo, sold online on a subscription model, open the market to prediabetic and wellness consumers.

What to Watch

CGM faces real constraints. Accuracy can vary between device generations and in high-acuity hospital settings. Competition from traditional blood glucose meters persists in price-sensitive markets, though that threat is fading as CGMs get cheaper and gain wider insurance coverage. The next phase of competition will likely turn on affordability, longer wear, OTC adoption, and how well each player integrates into the wider diabetes care ecosystem.

Go Deeper The full report covers 20+ countries, company profiles, competitive benchmarking, and segment forecasts through 2033. Customize This Report: add regions, segments, or competitor detail, with 20% free customization.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today